What is Rosuast?
Rosuast (Rosuast) belongs to a a group of drugs called HMG CoA reductase inhibitors, or "statins." Rosuast reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).
Rosuast is used in adults and children who are at least 8 years old to lower cholesterol and triglycerides (types of fat) in the blood and to slow the build-up of plaque (fatty deposits) in your blood vessels.
Rosuast is also used to lower the risk of stroke, heart attack, and other heart complications in certain people with diabetes, coronary heart disease, or other risk factors.
Rosuast is also used to treat hereditary forms of high cholesterol, including the heterozygous type (inherited from one parent) and the homozygous type (inherited from both parents). For the heterozygous type, Rosuast can be used in children who are at least 8 years old. For the homozygous type, Rosuast can be used in children as young as 7 years old.
Rosuast indications
Rosuast should be used as an adjunct to diet when the response to diet and exercise is inadequate.
Prevention of Cardiovascular Events: In adult patients with an increased risk of atherosclerotic cardiovascular disease based on the presence of cardiovascular disease risk markers such as an elevated hsCRP level, age, hypertension, low HDL-C, smoking or a family history of premature coronary heart disease, Rosuast is indicated to reduce total mortality and the risk of major cardiovascular events (cardiovascular death, stroke, MI, unstable angina, or arterial revascularization).
In Adult Patients with Hypercholesterolaemia: Rosuast is indicated to: Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDL-cholesterol in patients with primary hypercholesterolaemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). Rosuast also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG, the LDL-C/HDL-C, total C/HDL-C, nonHDL-C/HDL-C, ApoB/ApoA-I ratios and increases ApoA-I in these populations.
Treat patients with primary dysbetalipoproteinaemia (Fredrickson Type III hyper lipoproteinaemia).
Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia).
Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolaemia, as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or alone if such treatments are unavailable.
Slow or delay the progression of atherosclerosis.
Children and Adolescents 6 to 17 Years of Age: Rosuast is indicated to reduce the Total Cholesterol, LDL-C and Apo B in patients with heterozygous familial hypercholesterolaemia (HeFH).
How should I use Rosuast?
Use Rosuast as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Rosuast. Talk to your pharmacist if you have questions about this information.
- Take Rosuast by mouth with or without food.
- Swallow the tablets whole.
- If you also take an antacid that has aluminum or magnesium in it, take it at least 2 hours after taking Rosuast. Check with your doctor if you have any questions.
- Taking Rosuast at the same time each day will help you remember to take it.
- Continue to take Rosuast even if you feel well. Do not miss any doses.
- If you miss a dose of Rosuast, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once or within 12 hours of each other.
Ask your health care provider any questions you may have about how to use Rosuast.
Uses of Rosuast in details
- Rosuast is used for the treatment of high cholesterol, high LDL, high triglycerides and low HDL in addition to diet, when response to non-medicine options (diet, exercise and weight loss) is not adequate.
- It is also used to lower the risk of stroke, heart attack, or other heart complications in people who are at high risk of heart diseases, as an adjuvant to correction of the risk factors.
Rosuast description
Rosuast also contains the following inactive ingredients: Tribasic calcium phosphate, microcrystalline cellulose (PH 102), butylated hydroxy toluene, povidone K-30, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Instacoat universal white IH, purified water; color: Titanium dioxide.
Rosuast is a synthetic lipid-lowering agent for oral administration. The chemical name for Rosuast calcium is bis[(E)-7-[4(4-fluorophenyl)-6-isopropyl 2[methyl (methylsulfonyl) amino] pyrimidin-5-yl](3R,5S)3,5-dihydroxyhept-6-enoic acid] calcium salt. The empirical formula is (C22H27FN3O6S)2Ca and the molecular weight is 1001.14.
Rosuast dosage
General Dosing Information: The dose range for Rosuast is 5-40 mg orally once daily.
Rosuast can be administered as a single dose at any time of the day, with or without food. When initiating Rosuast therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate Rosuast starting dose should first be utilized, and only then titrated according to the patient's response and individualized goal of therapy.
The 40 mg dose of Rosuast should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose.
Hyperlipidemia, Mixed Dyslipidemia, Hypertriglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) and Slowing of the Progression of Atherosclerosis: The recommended starting dose of Rosuast is 10 mg dose once daily. For patients with marked hyperlipidemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20 mg starting dose may be considered.
After initiation or upon titration of Rosuast, lipid levels should be analyzed within 2-4 weeks and the dosage adjusted accordingly.
Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years): The usual dose range of Rosuast is 5-20 mg/day; the maximum recommended dose is 20 mg/day (doses >20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy. Adjustments should be made at intervals of ≥4 weeks.
Homozygous Familial Hypercholesterolemia: The recommended starting dose of Rosuast is 20 mg once daily. Response to therapy should be estimated from pre-aphereses LDL-C levels.
Dosage in Asian Patients: Initiation of Rosuast therapy with 5 mg once daily should be considered for Asian patients.
Use with Cyclosporine or Lopinavir/Ritonavir: In patients taking cyclosporine, the dose of Rosuast should be limited to 5 mg once daily. In patients taking a combination of lopinavir and ritonavir, the dose of Rosuast should be limited to 10 mg once daily.
Concomitant Lipid-Lowering Therapy: The risk of skeletal muscle effects may be enhanced when Rosuast is used in combination with niacin or fenofibrate; a reduction in Rosuast is used in combination with gemfibrozil, the dose of Rosuast should be limited to 10 mg daily.
Dosage in Patients with Severe Renal Impairment: For patients with severe renal impairment (CrCl <30 mL/min/1.73 m2) not on hemodialysis, dosing of Rosuast should be started at 5 mg once daily and should not exceed 10 mg once daily.
Rosuast interactions
See also:
What other drugs will affect Rosuast?
Effect of Co-Administered Medicinal Products on Rosuast: In vitro and in vivo data indicate that Rosuast has no clinically significant cytochrome P450 interactions (as a substrate, inhibitor or inducer). Rosuast is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of Rosuast with medicinal products that are inhibitors of these transporter proteins may result in increased Rosuast plasma concentrations and an increased risk of myopathy.
Interactions Requiring Rosuast Dose Adjustments : When it is necessary to co-administer Rosuast with other medicinal products known to increase exposure to Rosuast, doses of Rosuast should be adjusted. It is recommended that prescribers consult the relevant product information when considering administration of such products together with Rosuast. Start with a 5 mg once daily dose of Rosuast if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of Rosuast should be adjusted so that the expected Rosuast exposure would not likely exceed that of a 40 mg daily dose of Rosuast taken without interacting medicinal products, for example a 5 mg dose of Rosuast with ciclosporin (7.1-fold increase in exposure), a 10 mg dose of Rosuast with ritonavir/atazanavir combination (3.1-fold increase) and a 20 mg dose of Rosuast with gemfibrozil (1.9-fold increase).
Other Interacting Medicinal Products: Antacid: The simultaneous dosing of Rosuast with an antacid suspension containing aluminum and magnesium hydroxide resulted in a decrease in Rosuast plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after Rosuast. The clinical relevance of this interaction has not been studied.
Fusidic Acid: Interaction studies with Rosuast and fusidic acid have not been conducted. As with other statins, muscle related events, including rhabdomyolysis, have been reported in post-marketing experience with Rosuast and fusidic acid given concurrently. Patients should be closely monitored and temporary suspension of Rosuast treatment may be appropriate.
Effect of Rosuast on Co-Administered Medicinal Products: Warfarin: The pharmacokinetics of warfarin are not significantly affected following co-administration with Rosuast. However, as with other HMG-CoA reductase inhibitors, co-administration of Rosuast and warfarin may result in a rise in INR compared to warfarin alone. In patients taking vitamin K antagonists monitoring of INR is recommended both at initiation or cessation of therapy with Rosuast or following dose adjustment.
Fenofibrates/Fibric Acid Derivatives: Although no pharmacokinetic interaction between Rosuast and fenofibrate was observed; a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate and other fibric acids, including nicotinic acid, may increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors.
Cyclosporin: Co-administration of Rosuast with cyclosporin resulted in no significant changes in cyclosporin plasma concentration.
Other Medications: There were no clinically significant interactions with an oral contraceptive, digoxin, ezetimibe, or fenofibrate.
In clinical studies Rosuast was co-administered with antihypertensive agents, antidiabetic agents and hormone replacement therapy. These studies did not produce any evidence of clinically significant adverse interactions.
Rosuast side effects
See also:
What are the possible side effects of Rosuast?
Rosuast is generally well tolerated. The adverse events seen with Rosuast are generally mild and transient. In controlled clinical trials less than 4% of Rosuast treated patients were withdrawn due to adverse events. This withdrawal rate was comparable to that reported in patients receiving placebo.
Common (≥1/100, <1/10): Headache, myalgia, asthenia, constipation, dizziness, nausea, abdominal pain, diabetes mellitus*.
Uncommon (≥1/1000, <1/100): Pruritus, rash and urticaria.
Rare (≥1/10,000, <1/1000): Myopathy (including myositis), hypersensitivity reactions (including angioedema), rhabdomyolysis, pancreatitis.
*Observed in the JUPITER study (reported overall frequency 2.8% in Rosuast and 2.3% in placebo) primarily in patients already at high risk for developing diabetes.
As with other HMG CoA reductase inhibitors, the incidence of adverse drug reactions tends to increase with increasing dose.
Skeletal Muscle Effects: Rare cases of rhabdomyolysis, which were occasionally associated with impairment of renal function, have been reported with Rosuast and with other marketed statins.
Laboratory Effects: As with other HMG-CoA reductase inhibitors, a dose-related increase in liver transaminases and CK has been observed in a small number of patients taking Rosuast. Increases in HbA1c have also been observed in patients treated with Rosuast. Abnormal urinalysis testing (dipstick-positive proteinuria) has been seen in a small number of patients taking Rosuast and other HMG-CoA reductase inhibitors. The protein detected was mostly tubular in origin. In most cases, proteinuria decreases or disappears spontaneously on continued therapy, and is not predictive of acute or progressive renal disease.
Other Effects: In a long-term controlled clinical trial Rosuast was shown to have no harmful effects on the ocular lens.
In Rosuast treated patients, there was no impairment of adrenocortical function.
Post Marketing Experience: In addition to the previously mentioned effects, the following adverse events have been reported during post marketing experience of Rosuast: Haematological Disorders: Frequency Unknown: Thrombocytopenia.
Hepatobiliary Disorders: Very Rare: Jaundice, hepatitis. Rare: Increased hepatic transaminases.
Musculoskeletal Disorder: Frequency Unknown: Immune-mediated necrotising myopathy. Very Rare: Arthralgia.
As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis in post-marketing use is higher at the highest marketed dose.
Nervous System Disorder: Very Rare: Memory loss. Frequency Unknown: Peripheral neuropathy.
Psychiatric Disorders: Frequency Unknown: Depression, sleep disorders (including insomnia and nightmares).
Reproductive System and Breast Disorders: Frequency Unknown: Gynaecomastia.
Children and Adolescents 6 to 17 Years of Age: The safety profile of Rosuast is similar in children or adolescent patients and adults although CK elevations >10 x ULN and muscle symptoms following exercise or increased physical activity, which resolved with continued treatment, were observed more frequently in clinical trial of children and adolescents. However, the same special warnings and special precautions for use in adults also apply to children and adolescents.
Rosuast contraindications
See also:
What is the most important information I should know about Rosuast?
Hypersensitivity to Rosuast or to any of the excipients of Rosuast Sandoz.
Hepatic impairment; severe renal impairment; repeated or unexplained muscle aches or pain (myopathy); ciclosporin (eg, used after organ transplants).
In addition, the 40 mg dose of Rosuast Sandoz is contraindicated in: Repeated or unexplained muscle aches or pains (myopathy), a personal or family history of muscle problems or a previous history of muscle problems when taking other cholesterol-lowering drugs; moderate renal impairment; thyroid gland disorders; regular consumption of large amounts of alcohol; if taking fibrates to lower cholesterol; Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).
Use in pregnancy & lactation: Rosuast Sandoz should not be taken by pregnant and breastfeeding women. If the patient become pregnant while taking Rosuast Sandoz, stop taking it immediately and inform the physician. Women should avoid becoming pregnant while taking Rosuast Sandoz by using suitable contraception.
Active ingredient matches for Rosuast:
| Unit description / dosage (Manufacturer) | Price, USD |
| ROSUAST 10MG TABLET 1 strip / 10 tablets each (Astorion Pharmaceuticals Pvt Ltd) | $ 0.87 |
List of Rosuast substitutes (brand and generic names): | |
| Rosu Hdl | |
| Rosu Hdl 5mg Tablet (Morepen Laboratories Ltd) | $ 0.08 |
| Rosuben (Greece) | |
| ROSUBID | |
| ROSUBID 10MG TABLET 1 strip / 10 tablets each (Jarun Pharmaceuticals) | $ 0.79 |
| ROSUCAD (India) | |
| ROSUCAD tab 5 mg x 10's (Cadell) | $ 0.47 |
| ROSUCAD tab 10 mg x 10's (Cadell) | $ 0.84 |
| Rosucard (Bulgaria, Croatia (Hrvatska), Estonia) | |
| ROSUCARD -10 TABLET 1 strip / 10 tablets each (Tycoon Pharmaceuticals Pvt Ltd) | $ 1.20 |
| ROSUCARD -20 TABLET 1 strip / 10 tablets each (Tycoon Pharmaceuticals Pvt Ltd) | $ 2.41 |
| ROSUCARD -5 TABLET 1 strip / 10 tablets each (Tycoon Pharmaceuticals Pvt Ltd) | $ 0.66 |
| Rosucard 10mg Tablet (Tycoon Pharmaceuticals Pvt Ltd) | $ 0.13 |
| Rosucard 20mg Tablet (Tycoon Pharmaceuticals Pvt Ltd) | $ 0.24 |
| Rosucard 5mg Tablet (Tycoon Pharmaceuticals Pvt Ltd) | $ 0.07 |
| Rosucard Sanofi (Singapore) | |
| Rosucard Sanofi FC tab 10 mg 30's (sanofi-aventis) | |
| Rosucard Sanofi FC tab 20 mg 30's (sanofi-aventis) | |
| Rosucard Sanofi FC tab 40 mg 30's (sanofi-aventis) | |
| ROSUCHEK | |
| ROSUCHEK 10 MG TABLET 1 strip / 10 tablets each (Indoco Remedies Ltd) | $ 1.01 |
| ROSUCHEK 5 MG TABLET 1 strip / 10 tablets each (Indoco Remedies Ltd) | $ 0.57 |
| Rosuchek 10mg Tablet (Indoco Remedies Ltd) | $ 0.11 |
| Rosuchek 5mg Tablet (Indoco Remedies Ltd) | $ 0.06 |
| Rosuchen (Estonia, Latvia, Lithuania, Romania) | |
| ROSUCHOL | |
| ROSUCHOL 10MG TABLET 1 strip / 10 tablets each (Ajanta Pharma Ltd) | $ 3.23 |
| ROSUCHOL 5MG TABLET 1 strip / 10 tablets each (Ajanta Pharma Ltd) | $ 1.94 |
| Rosuchol 5mg Tablet (Ajanta Pharma Ltd) | $ 0.19 |
| ROSUCIA | |
| ROSUCIA 10 MG TABLET 1 strip / 10 tablets each (Precia Pharma) | $ 1.19 |
| ROSUCIA 20 MG TABLET 1 strip / 10 tablets each (Precia Pharma) | $ 2.40 |
| ROSUCIA 40 MG TABLET 1 strip / 10 tablets each (Precia Pharma) | $ 4.47 |
| ROSUCIA 5 MG TABLET 1 strip / 10 tablets each (Precia Pharma) | $ 0.68 |
| Rosucia 10mg Tablet (Precia Pharma) | $ 0.12 |
| Rosucia 20mg Tablet (Precia Pharma) | $ 0.24 |
| Rosucia 40mg Tablet (Precia Pharma) | $ 0.45 |
| Rosucia 5mg Tablet (Precia Pharma) | $ 0.07 |
| Rosucia Gold Tablet (Precia Pharma) | $ 0.12 |
| Rosucol (Argentina, Colombia, Philippines) | |
| Rosucol 10 mg x 30's (Ajanta Pharma Phil) | $ 10.97 |
| Rosucol 20 mg x 30's (Ajanta Pharma Phil) | $ 17.56 |
| Rosucol FC tab 10 mg 30's (Ajanta Pharma Phil) | |
| Rosucol FC tab 20 mg 30's (Ajanta Pharma Phil) | |
| Rosucol FC tab 5 mg 30's (Ajanta Pharma Phil) | |
| Rosucor (Turkey) | |
| ROSUCORT | |
| ROSUCORT 10mg Tablet (Unifab pharmaceuticals) | $ 0.12 |
| ROSUCREST | |
| ROSUCREST 10 MG TABLET 1 strip / 10 tablets each (C M R Life Sciences) | $ 1.35 |
| ROSUCREST 20 MG TABLET 1 strip / 10 tablets each (C M R Life Sciences) | $ 2.41 |
| ROSUCREST 40 MG TABLET 1 strip / 10 tablets each (C M R Life Sciences) | $ 4.16 |
| ROSUCREST 5 MG TABLET 1 strip / 10 tablets each (C M R Life Sciences) | $ 0.80 |
See 1847 substitutes for Rosuast | |
References
- DailyMed. "ROSUVASTATIN CALCIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Rosuvastatin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Rosuvastatin". http://www.drugbank.ca/drugs/DB01098 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Rosuast are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Rosuast. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
